Dec 31, 2025 • MarketBeat
NEUTRAL
Boston Trust Walden Corp Sells 53,026 Shares of Quest Diagnostics Incorporated $DGX
Boston Trust Walden Corp significantly reduced its stake in Quest Diagnostics Incorporated, selling 53,026 shares during the third quarter, resulting in holdings worth $5.64 million. Despite this reduction, other institutional investors have recently increased their positions in the medical research company. Quest Diagnostics reported strong quarterly earnings, beating analyst estimates, and announced a quarterly dividend of $0.80 per share.
Dec 30, 2025 • Business Wire
SOMEWHAT-BULLISH
NeoGenomics Appoints Diagnostics and Lab Services Industry Veteran John P. “Jack” Kenny to its Board of Directors
NeoGenomics, Inc. has appointed John P. “Jack” Kenny, a diagnostics and lab services industry veteran, to its Board of Directors. Mr. Kenny brings over three decades of executive, commercial, and operational experience and will fill the seat vacated by Dr. Alison Hannah. The company anticipates his expertise will significantly contribute to their advancements in cancer testing, particularly in NGS and MRD.
Dec 30, 2025 • MarketBeat
NEUTRAL
Copeland Capital Management LLC Sells 7,889 Shares of Quest Diagnostics Incorporated $DGX
Copeland Capital Management LLC reduced its stake in Quest Diagnostics Incorporated by 4.5% during the third quarter, selling 7,889 shares and retaining 168,375 shares valued at approximately $32.09 million. This sale comes amidst significant insider selling, with SVP Mark Delaney and CEO J. E. Davis also disposing of shares worth millions. Despite the insider and institutional selling, Quest Diagnostics beat Q3 earnings estimates, issued strong FY2025 guidance, and analysts maintain a "Moderate Buy" rating with an average target price of $197.27.
Dec 28, 2025 • MarketBeat
NEUTRAL
Harbor Capital Advisors Inc. Has $596,000 Stake in Quest Diagnostics Incorporated $DGX
Harbor Capital Advisors Inc. reduced its stake in Quest Diagnostics (NYSE:DGX) by 71% in the third quarter, now holding 3,128 shares valued at $596,000. Despite this, other institutional investors have increased their positions, with collectively 88.06% of the stock owned by institutional investors and hedge funds. Quest Diagnostics surpassed Q3 earnings expectations, reporting EPS of $2.60 against an anticipated $2.51, and revealed intentions to pay a quarterly dividend of $0.80 per share.
Dec 26, 2025 • MarketBeat
NEUTRAL
Pacer Advisors Inc. Grows Stock Holdings in Quest Diagnostics Incorporated $DGX
Pacer Advisors Inc. significantly increased its stake in Quest Diagnostics Incorporated by 2,531.6% in the third quarter of 2025, bringing its total ownership to 450,898 shares valued at $85.93 million. This increase makes Pacer Advisors Inc. a notable institutional investor in Quest Diagnostics, which recently reported strong Q3 earnings, beating analyst estimates, and announced a quarterly dividend of $0.80 per share. The medical research company holds a "Moderate Buy" consensus rating from analysts with an average target price of $197.27.
Dec 26, 2025 • MarketBeat
SOMEWHAT-BULLISH
Assenagon Asset Management S.A. Lowers Stake in Quest Diagnostics Incorporated $DGX
Assenagon Asset Management S.A. significantly reduced its stake in Quest Diagnostics (NYSE:DGX) by 73.2% in Q3, selling 15,248 shares. Despite this, Quest Diagnostics reported strong Q3 earnings, beating analyst expectations with $2.60 EPS and $2.82 billion in revenue, and issued positive FY2025 EPS guidance. The company also announced a quarterly dividend of $0.80 per share, while institutional investors hold approximately 88.06% of the company's stock.